Massive Study Links Teen Marijuana Use to Double the Risk of Serious Mental Illness

A major study published in JAMA Health Forum has found that adolescents who use cannabis are twice as likely to develop serious psychiatric conditions, including psychotic and bipolar disorders, by young adulthood. Researchers tracked over 460,000 individuals from age 13 through 26, identifying a significant correlation between any self-reported use and subsequent mental health diagnoses. These findings arrive as the cannabis industry faces increasing scrutiny over product potency and marketing practices, potentially fueling calls for stricter regulatory oversight and public health interventions.

The research, conducted by a coalition including Kaiser Permanente and the University of California, San Francisco, analyzed electronic health records of 463,396 adolescents between 2016 and 2023. The data revealed that teenagers who reported using cannabis within the previous year faced substantially higher risks of developing psychotic disorders, bipolar disorder, depression, and anxiety. Notably, the risk for both psychotic and bipolar disorders approximately doubled among those who used cannabis, with the average psychiatric diagnosis occurring 1.7 to 2.3 years after the initial report of use.

Lead author Kelly Young-Wolff, Ph.D., emphasized that the study accounted for prior mental health conditions and other substance use, yet still found a substantially higher risk of psychiatric disorders. Unlike previous studies that focused primarily on heavy use or clinical cannabis use disorders, this research examined any self-reported use captured during routine pediatric screenings. The study also highlighted socioeconomic disparities, noting that cannabis use was more prevalent among adolescents enrolled in Medicaid or living in disadvantaged neighborhoods, suggesting that continued commercialization could exacerbate existing mental health inequalities.

The findings have immediate implications for the cannabis sector, particularly regarding product standards and marketing. Dr. Lynn Silver of the Public Health Institute’s Getting it Right from the Start program argued that the increasing potency of cannabis—with California flower often exceeding 20% THC and concentrates reaching 95%—necessitates an urgent public health response. Silver called for measures to reduce product potency, limit youth exposure, and restrict aggressive marketing, framing adolescent cannabis use as a serious health issue rather than a benign behavior that the industry can ignore.